Trials / Completed
CompletedNCT00570310
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
A Double-Blind, Placebo-Controlled, Enriched-Enrollment, Randomized Withdrawal Study to Evaluate an Optimal Methodology for Conducting Proof of Concept Trials in Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin as a Test Drug
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.
Conditions
- Neuralgia, Postherpetic
- Diabetic Neuropathy
- Painful Small-Fiber Neuropathy
- Idiopathic Distal Sensory Polyneuropathy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Comparator: pregabalin | pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks |
| DRUG | Comparator: Placebo (unspecified) | pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2007-12-10
- Last updated
- 2015-05-07
- Results posted
- 2010-02-05
Source: ClinicalTrials.gov record NCT00570310. Inclusion in this directory is not an endorsement.